Vaccines for the prevention of meningococcal disease in children

M. Soriano-Gabarró*, James M. Stuart, Nancy E. Rosenstein

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    14 Citations (Scopus)


    Neisseria meningitidis is one of the most feared infections in pediatrics as the result of its rapid progression, high fatality rate, and frequent occurrence of sequelae. The 5 major meningococcal serogroups associated with disease are A, B, C, Y, and W-135. Currently available polysaccharide vaccines are effective in preventing disease caused by serogroups A, C, Y, and W-135 in older children and adults but do not elicit good long-term protection in young children. Vaccines that protect against serogroup B disease are still in development. As with the Haemophilus influenzae type b and pneumococcal polysaccharide vaccines, conjugation of the polysaccharide vaccine to a protein carrier dramatically changes vaccine characteristics, with resulting efficacy in infants. New meningococcal conjugate vaccines against serogroups A, C, Y, and W-135 are being developed. A serogroup C conjugate vaccine has been introduced successfully into the routine childhood schedule in the United Kingdom. New meningococcal conjugate vaccines are likely to have a dramatic effect on the burden of meningococcal disease within the next decade.

    Original languageEnglish
    Pages (from-to)182-189
    Number of pages8
    JournalSeminars in Pediatric Infectious Diseases
    Issue number3
    Publication statusPublished - Jul 2002


    Dive into the research topics of 'Vaccines for the prevention of meningococcal disease in children'. Together they form a unique fingerprint.

    Cite this